CIRCLE WITH A DOT

· New review in Dovepress states that #LongCOVID, #MECFS & #POTS should be classified as neuroimmune disorders.
· Wearable activity tracker notifications may not be a reliable way to mitigate or reduce PEM, new study in Nature Communications
· Small, phase one study is recruiting in Sacramento & San Francisco, CA to test advanced techniques in total body imaging to improve understanding of “tissue-level immune dysregulation” in the disease

Research updates, February 17 - The Sick Times

A new review in Dovepress states that Long COVID, myalgic encephalomyelitis (ME), and postural orthostatic tachycardia syndrome (POTS) should be classified as neuroimmune disorders.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates #COVID

@lovinurbanism Zum Glück wäre sowas irl nie denkbar. Uff

· A large study recently connected “chronic absenteeism” to pediatric #LongCOVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic
· A small mechanistic study in Brain, Behavior, & Immunity – Health found that immunoglobulin G (IgG), isolated from people with #MECFS, can destroy mitochondria in endothelial cells
· ADDRESS-LC has opened two more study sites: a new one in California and one in Connecticut

Research updates, February 10 - The Sick Times

A large study recently connected “chronic absenteeism” to pediatric Long COVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates

· The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for #LongCOVID
· Long COVID isn’t being consistently captured around the world due to differences in sociological factors, diagnostic tools, and healthcare access
· A phase two trial for Long COVID-associated postural orthostatic tachycardia syndrome (#POTS) is testing a product called 2-hydroxybenzylamine (2-HOBA)

Research updates, February 3 - The Sick Times

The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for Long COVID.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates #COVID

· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda

Research updates, January 27 - The Sick Times

A large prospective cohort study published in Infectious Diseases found that a majority of people with Long COVID did not recover.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates

· A new study in eBioMedicine found neurological #LongCOVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation tied to Alzheimer’s disease
· A new “state-of-the-art” review on #POTS highlighted that the multisystemic condition is disabling, causes societal & economic withdrawal
· A phase II clinical trial testing efficacy & safety Uplizna (Inebilizumab) in LC & #MECFS recently announced by German Ministry of Research

Research updates, January 20 - The Sick Times

A new study in eBioMedicine found neurological Long COVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation that has been tied to Alzheimer's disease.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates

· A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from #COVID19
· A new study published in Molecular & Cellular Proteomics found further evidence of abnormalities in post-exertional malaise #PEM
· A small phase two clinical trial is testing #Ketamine for #LongCOVID fatigue and cognitive function

Research updates, January 13 - The Sick Times

A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from COVID-19.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates #TheSickTimes

· 43% of Latino people reported symptoms of #LongCOVID in a new survey study published in Journal of General Internal Medicine
· A case series for Long COVID using a combination of Paxlovid, valacyclovir (Valtrex) and celecoxib (Celebrex), was recently published in Frontiers of Immunology
· A new phase II clinical trial for Long COVID was recently announced in the Netherlands

Research updates, January 6 - The Sick Times

43% of Latino people reported symptoms of Long COVID in a new survey study published in Journal of General Internal Medicine. The survey included the responses of 1,500 participants in Washington state who had confirmed COVID-19 cases between 2020 and 2022.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates #COVID

· Two recent studies state that #LongCOVID is an occupational disease.
· Vanderbilt researchers are conducting an immune profiling study on people with Long COVID and postural orthostatic tachycardia syndrome (#POTS)
· A new phase two remote clinical trial was recently announced for myalgic encephalomyelitis (ME) #MECFS

Research updates, December 23 - The Sick Times

Two recent studies state that Long COVID is an occupational disease.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates

· New study in Cureus found veterans diagnosed with #LongCOVID at 34% higher risk of visiting emergency department 6 months after infection
· “Our data demonstrate that [LC] is characterized by chronic inflammation, immune exhaustion, & metabolic dysregulation,” scientists conclud in new study published in Nature Immunology
· U.K. charity ME Association awards £1.1 million in funding to the Imperial College to study immunological profiles of LC & #MECFS

Research updates, December 16 - The Sick Times

A new observational study in Cureus found that veterans diagnosed with Long COVID had a 34% higher risk of visiting the emergency department (ED) six months following infection than those without Long COVID.

The Sick Times - Chronicling the Long Covid crisis (thesicktimes.org)

#ResearchUpdates

· A new study in the International Journal of Infectious Diseases examines how #COVID19 impacts the immune system
· German government announced just over €500 million ($582 million USD) in funding for infection-associated diseases, including #LongCOVID & #MECFS
· A preprint using data from the DecodeME study found more than 250 genes associated with ME, 76 of which were shared with Long COVID

https://thesicktimes.org/2025/12/09/research-updates-december-9/

#researchupdates

· Large retrospective cohort study of over 18,000 births found infants exposed to #COVID19 during pregnancy were more likely to have adverse neurodevelopmental diagnoses as 3 years olds
· Another study has found that common diabetes drug metformin may help reduce risk of #LongCOVID
· NIH is recruiting for a small observational study to understand if people with neurological symptoms of Long COVID have inactive [?] remnants of SARS-CoV-2 in their bodies

https://thesicktimes.org/2025/12/02/research-updates-december-2/

#ResearchUpdates

· A review paper summarizes the vast global costs of #LongCOVID, it is estimated to have an average annual burden of at least $1 trillion globally per year
· A small study in Nature found SARS-CoV-2 in the organs of fetuses from people who were infected with the virus while pregnant
· The National Institutes of Health’s RECOVER-Treating Long COVID initiative released a draft of its protocol for the low-dose naltrexone trial for people ages 6-25

https://thesicktimes.org/2025/11/25/research-updates-november-25/

#ResearchUpdates #covid19

· New mechanistic study in Science Translational Medicine identifies Epstein-Barr virus as a potential trigger of the autoimmune disease systemic #lupus erythematosus
· Michael Peluso of UCSF shared updates on two upcoming #LongCOVID trials:
- One potential trial called COMBAT-LC plans to test the combination of the monoclonal antibody Pemgarda with the antiviral Paxlovid
- The second trial INTERRUPT-LC will test the bladder cancer drug Anktiva

https://thesicktimes.org/2025/11/18/research-updates-november-18/

#ResearchUpdates

· The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating #LongCOVID
· Scientists are revealing more about microclots and Long COVID. A recent study in the Journal of Medical Virology found a strong association between microclots and net-like structures that some white blood cells (called neutrophils) release to attack pathogens
· A study about #MECFS was retracted by the journal Food Science and Nutrition

https://thesicktimes.org/2025/11/11/research-updates-november-11/

#ResearchUpdates #COVID19

· The #German government is cutting millions of euros in #LongCOVID funding
· Large electronic cohort study from Sweden found that 1.4% of people with a documented #COVID19 case were officially diagnosed with Long COVID by medical providers
· Lidia Morawska, Australian scientist who alerted the world that SARS-CoV-2 was airborne, was recently recognized for her work with a prestigious science prize for “pioneering research about the air we breathe"

https://thesicktimes.org/2025/11/04/research-updates-november-4/

#ResearchUpdates

· A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in #COVID19.

· A recent paper found that low-dose rapamycin alleviated symptoms of fatigue and post-exertional malaise in people with #MECFS.

· A phase 2 clinical trial is recruiting in Boston, Massachusetts to test the drugs Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) for ME.

https://thesicktimes.org/2025/10/28/research-updates-october-28/

#ResearchUpdates #LongCOVID

· A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for #LongCOVID
· A white paper from the Patient-Led Research Collaborative assessed Long COVID in India
· Researchers recently critiqued the study design and conclusions of a controversial 2024 study on ME, which asserted that the disease was a result of altered “effort preference” and deconditioning

https://thesicktimes.org/2025/10/21/research-updates-october-21/

#ResearchUpdates #COVID19

· A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer
· A small study in the Journal of Translation Medicine found a potential blood test for myalgic encephalomyelitis (ME)
· Researchers have developed a device that may be able to accurately measure fibrinaloid microclots in children

https://thesicktimes.org/2025/10/14/research-updates-october-14/

#ResearchUpdates #COVID19 #MECFS

· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia

https://thesicktimes.org/2025/10/07/research-updates-october-7/

#COVID19 #ResearchUpdates